We are live on ! Find out more
STRO icon

Sutro Biopharma
STRO

122 hedge funds and large institutions have $118M invested in Sutro Biopharma in 2024 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 41 increasing their positions, 35 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

263% more call options, than puts

Call options by funds: $243K | Put options by funds: $67K

17% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 35

0.12% more ownership

Funds ownership: 7.63% → 7.75% (+0.12%)

6% less funds holding

Funds holding: 130 → 122 (-8)

23% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 30

46% less capital invested

Capital invested by funds: $216M → $118M (-$98.8M)

Holders
122
Holders Change
-8
Holders Change %
-6.15%
% of All Funds
1.61%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
23
Increased
41
Reduced
35
Closed
30
Calls
$243K
Puts
$67K
Net Calls
+$176K
Net Calls Change
+$29K

Top Buyers

Rank Fund Capital Flow
1
VPC
Vestal Point Capital
New York
+$7.85M
2
KCM
Kynam Capital Management
New Jersey
+$4.81M
3
Morgan Stanley
Morgan Stanley
New York
+$3.8M
4
BlackRock
BlackRock
New York
+$1.76M
5
Prudential Financial
Prudential Financial
New Jersey
+$1.3M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$4.96M
2
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
-$4.49M
3
EP
Eversept Partners
New York
-$3.5M
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$2.85M
5
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$2.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
HWM
101
HighMark Wealth Management
Minnesota
$4.14K – – –
AB
102
Amalgamated Bank
New York
$4K – – –
GFM
103
GF Fund Management
China
$3.19K +$5.28K +173 New
RS
104
R Squared
Hong Kong
$2.19K +$3.63K +119 New
BIG
105
Brooklyn Investment Group
New York
$2.09K +$3.48K +114 New
Simplex Trading
106
Simplex Trading
Illinois
$2K -$10.7K -349 -72%
GWP
107
Gen-Wealth Partners
Michigan
$1.92K – – –
CWP
108
Concord Wealth Partners
Virginia
$1.84K +$3.05K +100 New
SAM
109
Smartleaf Asset Management
Massachusetts
$945 +$885 +29 +132%
AF
110
Advisornet Financial
Minnesota
$920 – – –
BWL
111
Bogart Wealth LLC
Virginia
$920 – – –
ACM
112
Aquilo Capital Management
California
$916 -$2.33M -76,200 -100%
PA
113
Parallel Advisors
California
$856 – – –
CIAM
114
Caitong International Asset Management
Hong Kong
$644 +$1.07K +35 New
EWA
115
EverSource Wealth Advisors
Alabama
$112 +$183 +6 New
Nisa Investment Advisors
116
Nisa Investment Advisors
Missouri
$107 -$27.2K -890 -99%
AF
117
Allworth Financial
California
$99 +$153 +5 New
PNC Financial Services Group
118
PNC Financial Services Group
Pennsylvania
$94 – – –
Comerica Bank
119
Comerica Bank
Texas
$91 – – –
IA
120
IFP Advisors
Florida
$55 +$92 +3 New
FFA
121
Farther Finance Advisors
California
$17 – – –
SS
122
SBI Securities
Japan
$4 – – –
Bank of Montreal
123
Bank of Montreal
Ontario, Canada
– -$2.85M -81,496 Closed
Arrowstreet Capital
124
Arrowstreet Capital
Massachusetts
– -$2.55M -73,767 Closed
DM
125
Deerfield Management
New York
– -$1.25M -35,992 Closed
3 4
5
6 7

STRO Hedge Fund Activity: Q4 2024 in Review

122 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q4 2024, worth a combined $118M — down 46% from $216M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of STRO and 23 opened new positions — a net loss of 7 holders — while 35 trimmed existing stakes and 41 added.

The largest buyer was Vestal Point Capital, opening a new position worth an estimated $7.85M. The largest seller was Millennium Management, cutting an estimated $4.96M.

  • 122 institutional investors held Sutro Biopharma (STRO) as of Q4 2024, down from 130 in Q3 2024.
  • Funds reported $118M of Sutro Biopharma stock for Q4 2024, down 46% quarter-over-quarter.
  • 23 funds opened new Sutro Biopharma positions in Q4 2024 and 30 closed out, a net change of -7 holders.
  • The largest Sutro Biopharma buyer in Q4 2024 was Vestal Point Capital, an estimated $7.85M added.
  • The largest Sutro Biopharma seller in Q4 2024 was Millennium Management, an estimated $4.96M sold.

Based on aggregated 13F filings for Q4 2024.